Precision medicine for major unmet medical needs
About Us
Changing the way we treat disease
Our approach leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact.
News & Events
FDA Approval to Proceed with Phase 2 SPRING Trial of LHP588, a Next-generation Treatment for P. gingivalis-Positive Alzheimer’s Disease
- Phase 1 single ascending and multiple ascending dose studies previously completed demonstrate safety, tolerability and dosing to reach optimal target engagement
Lighthouse Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease
- Pre-IND meeting completed with US FDA.
-World-class clinical advisory board to support clinical development plans
Lighthouse Pharma completes acquisition of protease inhibitor portfolio from Quince Therapeutics
Events
​March 13, 2023: International Society for CNS Drug Development (ISCDD). Invited presentation: "Heterogeneity in Dementia and Precision Medicine"
May 30, 2023: American Society of Clinical Psychopharmacology (ASCP) Plenary Presentation and Poster, Pharmaceutical Pipeline session: "Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, a Second-Generation Gingipain Inhibitor for the Treatment of P. Gingivalis-Associated Dementia." View Poster
​
June 13-14, 2023 National Institute on Aging (NIA) : Invited presentation “Biology, mechanisms, oral microbiome and AD” during National Institute on Aging workshop, Dr. Stephen Dominy CSO, "Oral Health and Alzheimer’s Disease and Related Dementias” ​
​
June 22, 2023 Advancements in Treatment for an Aging population. Casey Lynch Interview with Portfolia CEO Trish Costello
​
June 16-20, 2023 Alzheimer's Association International Conference . Dr. Michael Detke, CMO "Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, a Second-Generation Gingipain Inhibitor for the Treatment of P. Gingivalis-Positive Alzheimer's disease" View Poster.
​
October 14-27, 2023 Clinical Trials in Alzheimer's Disease. Dr. Michael Detke, CMO "Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, a Second-Generation Gingipain Inhibitor for the Treatment of P. Gingivalis-Positive Alzheimer's disease" View Poster.
Leadership Team
Clinical Advisory Board
